公开(公告)号：US12173009B2

公开(公告)日：2024-12-24

申请号：US17944782

申请日：2022-09-14

Applicant: CELLTAXIS, LLC

Inventor： Damian O. Arnaiz ,  Greg Brown ,  Emmanuel Claret ,  Arwed Cleve ,  David Davey ,  William Guilford ,  Seock-Kyu Khim ,  Thomas Kirkland ,  Monica J. Kochanny ,  Amy Liang ,  David Light ,  John Parkinson ,  Guo Ping Wei ,  Bin Ye

IPC: C07D487/08 ,  C07C217/58 ,  C07C229/08 ,  C07C229/38 ,  C07C233/78 ,  C07C255/57 ,  C07C271/20 ,  C07D207/04 ,  C07D207/09 ,  C07D207/16 ,  C07D211/26 ,  C07D211/34 ,  C07D211/58 ,  C07D243/08 ,  C07D263/14 ,  C07D263/32 ,  C07D277/22 ,  C07D277/68 ,  C07D295/04 ,  C07D295/096 ,  C07D295/16 ,  C07D401/10 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D451/02 ,  C07D451/04

Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

公开(公告)号：US11267819B2

公开(公告)日：2022-03-08

申请号：US16738190

申请日：2020-01-09

Applicant: CELLTAXIS, LLC

Inventor： Damian O. Arnaiz ,  Greg Brown ,  Emmanuel Claret ,  Arwed Cleve ,  David Davey ,  William Guilford ,  Seock-Kyu Khim ,  Thomas Kirkland ,  Monica J. Kochanny ,  Amy Liang ,  David Light ,  John Parkinson ,  Guo Ping Wei ,  Bin Ye

IPC: C07D487/08 ,  C07C217/58 ,  C07C229/38 ,  C07C233/78 ,  C07C255/57 ,  C07C271/20 ,  C07D207/04 ,  C07D211/58 ,  C07D243/08 ,  C07D295/04 ,  C07D295/16 ,  C07D451/04 ,  C07D207/09 ,  C07D211/26 ,  C07D263/32 ,  C07D295/096 ,  C07D401/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07C229/08 ,  C07D263/14 ,  C07D401/12 ,  C07D207/16 ,  C07D211/34 ,  C07D277/22 ,  C07D277/68 ,  C07D451/02

Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

公开(公告)号：US20230250104A1

公开(公告)日：2023-08-10

申请号：US17944782

申请日：2022-09-14

Applicant: CELLTAXIS, LLC

Inventor： Damian O. Arnaiz ,  Greg Brown ,  Emmanuel Claret ,  Arwed Cleve ,  David Davey ,  William Guilford ,  Seock-Kyu Khim ,  Thomas Kirkland ,  Monica J. Kochanny ,  Amy Liang ,  David Light ,  John Parkinson ,  Guo Ping Wei ,  Bin Ye

IPC: C07D487/08 ,  C07C217/58 ,  C07C229/38 ,  C07C233/78 ,  C07C255/57 ,  C07C271/20 ,  C07D207/04 ,  C07D211/58 ,  C07D243/08 ,  C07D295/04 ,  C07D295/16 ,  C07D451/04 ,  C07D207/09 ,  C07D211/26 ,  C07D263/32 ,  C07D295/096 ,  C07D401/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07C229/08 ,  C07D263/14 ,  C07D401/12 ,  C07D207/16 ,  C07D211/34 ,  C07D277/22 ,  C07D277/68 ,  C07D451/02

CPC classification number: C07D487/08 ,  C07C217/58 ,  C07C229/38 ,  C07C233/78 ,  C07C255/57 ,  C07C271/20 ,  C07D207/04 ,  C07D211/58 ,  C07D243/08 ,  C07D295/04 ,  C07D295/16 ,  C07D451/04 ,  C07D207/09 ,  C07D211/26 ,  C07D263/32 ,  C07D295/096 ,  C07D401/10 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07C229/08 ,  C07D263/14 ,  C07D401/12 ,  C07D207/16 ,  C07D211/34 ,  C07D277/22 ,  C07D277/68 ,  C07D451/02 ,  C07C2601/14 ,  C07B2200/07

Abstract: This invention is directed to compounds of formula (I):




where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.